Combo Tx Yields ' Unprecedented ' Remission Rates in MCL (CME/CE)
(MedPage Today) -- BTK/BCL2 inhibition highly active in relapsed or refractory disease
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer & Oncology | Hematology